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Abstract The methionine cycle is a key pathway contribut-
ing to the regulation of human health, with well-established
involvement in cardiovascular diseases and cognitive func-
tion. Changes in one-carbon cycle metabolites have also
been associated with mild cognitive decline, vascular de-
mentia, and Alzheimer’s disease. Today, there is no single
analytical method to monitor both metabolites and co-factors
of the methionine cycle. To address this limitation, we here
report for the first time a new method for the simultaneous
quantitation of 17 metabolites in the methionine cycle,
which are homocysteic acid, taurine, serine, cysteine, gly-
cine, homocysteine, riboflavin, methionine, pyridoxine, cys-
tathionine, pyridoxamine, S-adenosylhomocysteine, S-
adenosylmethionine, betaine, choline, dimethylglycine, and
5-methyltetrahydrofolic acid. This multianalyte method, de-
veloped using ultra-performance liquid chromatography–tan-
dem mass spectrometry (UPLC–MS/MS), provides a highly
accurate and precise quantitation of these 17 metabolites for
both plasma and cerebrospinal fluid metabolite monitoring.
The method requires a simple sample preparation, which,
combined with a short chromatographic run time, ensures a
high sample throughput. This analytical strategy will thus
provide a novel metabolomics approach to be employed in
large-scale observational and intervention studies. We expect
such a robust method to be particularly relevant for broad
and deep molecular phenotyping of individuals in relation to
their nutritional requirements, health monitoring, and disease
risk management.
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Introduction
The coupling of the increased percentage of elderly in the
world’s population and the incidences of chronic diseases is
stimulating renewed interest in understanding the role of ge-
netics, environmental factors, and their interactions with indi-
vidual susceptibility to disease [1]. However, the determina-
tion of nutritional requirements for optimizing metabolism for
an individual or population remains challenging due to the
complexity of food macro- and micronutrient composition,
intersubject variability in physiological responses, environ-
mental, and genetic factors [2]. Over the last two decades,
the era of omics technologies has provided an innovative par-
adigm for exploring physiological and pathological processes
through broad and deep biological phenotyping [3]. The me-
thionine cycle is among the many central pathways that con-
tribute to human health. Dysfunction of this pathway has been
linked to cardiovascular disease, mild cognitive decline, vas-
cular dementia, and Alzheimer’s disease [4]. In addition, co-
factors derived from diet are crucial for proper functioning of
the methionine cycle. A key product of this pathway, S-
adenosylmethionine (SAM), is itself a co-factor and substrate
for methylation of DNA, protein, and RNA as well as
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biosynthetic reactions of key brain metabolites [5]. Hence,
optimizing this pathway through nutrition may protect the
brain from damage and reduce the risk of cardiovascular
events. Monitoring the activity of this pathway in response
to nutrition through metabolomics analysis (i.e., nutritional
metabolomics) would generate a more comprehensive under-
standing of the interplay between host, environment, and nu-
trient interactions [6]. In particular, mass spectrometry (MS)-
based metabolomics methods have demonstrated robust, ac-
curate, and precise quantitation of several homocysteine–me-
thionine cycle biomarkers in diverse biological matrices
[7–10]. However, no single and high-throughput method cur-
rently exists to monitor both metabolites and co-factors in the
methionine pathway. Most available analytical methods for
methionine pathway metabolites have so far deployed multi-
ple and typically separate chromatographic, derivatization,
and/or detection schemes to identify and quantify methionine,
sulfur-containing amino acids, homocysteine (HCy) and cys-
teine, S-adenosylmethionine/S-adenosylhomocysteine (SAM/
SAH), and B vitamins [11–15]. To address this limitation, we
have recently developed a new method for the simultaneous
quantitation of 13 metabolites and co-factors from the so-
called methionine pathway by liquid chromatography–tandem
mass spectrometry (LC–MS/MS) in red blood cells [16]. In
the present contribution, we introduce a further development
of the method to enable a highly accurate and precise quanti-
tation of 17metabolites in plasma, including homocysteic acid
(HA), taurine, serine, cysteine, glycine, homocysteine, ribo-
flavin, methionine, pyridoxine, cystathionine, pyridoxamine,
SAH, SAM, betaine, choline, dimethylglycine (DMG), and 5-
methyltetrahydrofolic acid (5-MTHF) (Fig. 1). This improved
method is also based on a simple sample preparation, which
combined to a short chromatographic run time ensures a high
sample throughput. This novel analytical strategy was also
successfully applied for cerebrospinal fluid (CSF) analysis.
Thus, this method provides a novel metabolomics approach
for large-scale observational and human intervention studies.
We demonstrate its applicability by analyzing plasma and
CSF samples from healthy elderly subjects and patients diag-
nosed with Alzheimer’s disease (AD).
Materials and methods
Materials LC–MS-grade acetonitrile (ACN), LC-grade meth-
anol (MeOH), formic acid, perfluoroheptanoic acid (PFHA),
ascorbic acid, sodium hydroxide (NaOH) 0.1 M, hydrochloric
acid (HCl), tris(2-carboxyethyl)phosphine (TCEP), dithiothre-
itol (DTT), and ammonium acetate (NH4OAc) were purchased
from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland).
Deionized water (R > 18ΩM/cm, TOC < 10 ppb) was used
throughout the experiments and produced by a Millipore-Q
water system (Millipore, Bedford, MA, USA).
HA, taurine, serine, cystine, glycine, homocystine (HCy2),
riboflavin, methionine, pyridoxine, cystathionine, SAH, pyridox-




nine-d3 standards were purchased from Sigma-Aldrich Chemie
GmbH.
HA-d4, serine-d3, pyridoxine-d2, cystathionine-d4, SAM-
d4, DMG-d6, choline-d9, and betaine-d11 were purchased from
CDN Isotopes (Pointe-Claire, Quebec, Canada). Cystine-d4,
homocystine-d8, and pyridoxamine-d3 were purchased from
Cambridge Isotopes Laboratories (Andover, MA, USA).
SAH-d4 was purchased from Cayman Chemical (Ann Arbor,
MI, USA). 5-MTHF-13C5 was purchased from Merck
(Schaffhausen, Switzerland).
Preparation of the individual standard and internal stan-
dard solutions Standard solutions were prepared individually
in 0.1MHCl (or in 10mmol/LNH4OAc, 0.1MNaOH, or in a
mixture ofMeOH/H2O depending on their solubility). Only 5-
MTHF was dissolved in a mixture of 10 mmol/L NH4OAc
with 10 % ascorbic acid and 2 % DTT in H2O to prevent
oxidation. The same dilution solvents were used for individual
internal standard (IS) stock solutions (Table S1, see Electronic
Supplementary Material (ESM)). Standard and IS solutions
were stored at −20 °C for up to 3 months.
Calibration curves and QC samples Calibration standards
were prepared by dilution of standard stock solutions in
ACN/H2O (5/95; v/v) to obtain seven calibration solutions
(calibrants 1 to 7) in micromolar range for HA, taurine,
serine, cystine, glycine, methionine, HCy2, DMG, betaine,
and choline and in nanomolar range for riboflavin, pyridox-
ine, cystathionine, pyridoxamine, SAH, SAM, and 5-MTHF
as described in Table S2 (see ESM). An IS working solution
was prepared by dilution of IS standard stock solutions in
ACN/H2O (5/95; v/v) (see ESM Table S3) and stored at
−20 °C for up to 3 months. Calibration samples were pre-
pared with each batch of samples and injected at both the
beginning and the end of the sample sequence. Fifty micro-
liters of each calibration solution was pipetted and trans-
ferred into a 1.5-mL microcentrifuge tube. A volume of 10
microliters of IS working solution was then added to these
solutions. Fifty microliters of TCEP (100 mg/mL) and then
140 μL of ACN/H2O (5/95; v/v) solution were furtherly
added to the mixture. The tubes were placed on an
autosampler rack and vortexed on a plate vortexer for
15 min at 1350 rpm. The solutions were transferred into
vials and ready for LC–MS/MS analysis. Quality controls
(QCs) at two different concentrations were added to each
batch of samples. The low QC (at the same concentration
as calibration level 3) and high QC (calibration level 6)
samples were prepared using the same protocol as the cali-
bration samples.
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LC–MS/MS instrumentation The instrumental methodolo-
gy was previously reported for red blood cell analysis [16] and
is fully described in the ESM (Table S4 and Table S5). Briefly,
a high-throughput method was developed using LC–MS/MS.
Separation and analysis were performed on an Accela
UHPLC 1250 Pump (Thermo Fisher Scientific Inc.,
Waltham, MA, USA) coupled to a TSQ Quantum Vantage
triple quadrupole (Thermo Fisher Scientific Inc., Waltham,
MA, USA) equipped with a heated electrospray ionization
(H-ESI) source. Chromatographic separation was obtained
using gradient elution on a reversed-phase UPLC XSelect
HSST3 2.5 μm, 100 × 2.1 mm I.D. column (Waters
Corporation, Milford, MA, USA). The injection volume was
10 μL and the total run time of analysis was 13 min.
Human sample collection for method validation The hu-
man sub-cohort was supplied from PrecisionMed, Inc. (CA,
USA, protocol 8009). This sub-cohort comprises 12 individ-
uals: 6 control subjects and 6 patients diagnosed with
Alzheimer’s disease (AD). All the subjects are aged 50 years
and older.
Plasma and CSF sample collection and processing Plasma
or CSF frozen samples were thawed and vortexed for 10 s. A
50-μL volume of plasma or CSF samples was transferred by
pipetting into a 1.5-mL microcentrifuge tube. Ten microliters
of IS solution was added to plasma or CSF samples. Fifty
microliters of TCEP solution and then 140 μL of methanol +
1 % FA were then added to the mixture. The tubes were
placed in a multitube vortexer for 15 min at 1350 rpm at
4 °C and centrifuged at 14,500 rpm for 5 min. The superna-
tants were pipetted and filtered through a 0.22-μm filter and
placed into vials for LC–MS/MS analysis.
Matrix effects Matrix effects were assessed by considering
the post-extraction IS analyte spiking. Two sets of samples
(five replicates for each set) were used: one containing the
IS analyte added to an extracted matrix (post-extraction
sample) and the other containing the IS analyte in the mobile
phase solvent. Both sets of samples were spiked with the
same concentration of IS analyte. Matrix effect values in
percent were calculated using the following equation: matrix
effect (%) = B/A * 100 (A =mean of external solution peak
area, B = post-extraction sample peak area).
Validation procedure The validation procedure involves
the following criteria: specificity and selectivity, limit of
detection (LOD) and limit of quantitation (LOQ), linearity,
trueness, precision (repeatability and intermediate preci-
sion), and recovery. Specificity and selectivity were
assessed using the retention time and mass spectrum profile
of pure standards and compared to the ones in unspiked
CSF and plasma samples.
Fig. 1 Metabolic pathway
involving the measured (blue)
metabolites from the
homocysteine–methionine cycle
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LOD and LOQwere evaluated based on the signal-to-noise
ratio (S/N), at least above 3 for the LOD and 10 for the LOQ
by injecting spiked plasma or CSF samples with the IS mix-
ture of all analytes.
The calibration curves were constructed, at each concentra-
tion level, by calculating the chromatographic peak area ratio
of the analyte and its IS for each metabolite.
Trueness and precision (repeatability and intermediate
precision) were assessed by spiking plasma and CSF sam-
ples at low, medium, and high levels in six replicates for
each level. For repeatability, six replicates were performed
by the same operator on three separate occasions in a
short period of time (less than 1 month). For intermediate
precision, the same protocol was followed with additional
analyses being carried out by two other individuals on a
total of six separated occasions.
Statistical analysis Two-sample Kolmogorov–Smirnov (KS)
tests were used to determine the statistical significance be-
tween gender distributions of metabolites. Uncorrected P
values less than 0.05 were considered significant. The statis-
tical software R v.3.2.2 [17] was used as a general platform
for such analyses, and the package ggplot2 [18] was used
for visualization.
Results and discussion
The analytical method analyzes 17metabolites involved in the
homocysteine–methionine cycle. The previously described in-
strumental methodology used for the RBC matrix [16] was
applied to the analysis of plasma and CSF samples. The ana-
lytical method extends the metabolite coverage, which now
also includes betaine, DMG, choline, and 5-MTHF acid. Such
an approach enables a more comprehensive assessment of
homocysteine contribution via methionine synthase but also
through betaine homocysteine methyltransferase (BHMT) to
the methionine metabolism. The BHMT pathway is particu-
larly active in both liver and kidney, which are the main organs
for storage of large amounts of betaine [19]. This metabolite is
actually distributed widely in plants and animals, particularly
in seafood, and an inadequate dietary intake leads to hypome-
thylation of proteins, RNA, and DNA. Inadequate levels of
betaine lead to disturbed hepatic protein metabolism,
expressed by elevated homocysteine concentrations and de-
creased SAM concentrations in plasma [20]. Less well known
are the correlations between betaine availability in plasma and
its concentration in the CSF. Changes in the methionine cycle
may be monitored by betaine–DMG conversion and the var-
iations in 5-MTHF concentrations in plasma. In addition to
betaine, choline is another important dietary methyl group
Fig. 2 Typical SRM chromatograms obtained for spiked CSF samples at the medium level
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donor particularly during folate deficiency [21]. Choline may
enter the homocysteine–methionine cycle through its oxida-
tion to betaine which is used as a substrate in the BHMT
reaction that links choline and betaine to the folate-
dependent methionine pathway. Our analytical method com-
bines LC with MS/MS which provides a high specificity and
sensitivity, as well as a fast run time (13 min). Compared to
our previous methodology for RBC analysis, the current
workflow for plasma and CSF does not require the same sam-
ple preparation, since there is no metabolite extraction from
cells. Sample treatment was optimized for plasma samples and
then applied to CSF samples. A simple and quick sample
preparation including protein precipitation and chemical re-
duction was required for total cysteine and total homocysteine
quantitation.
Extractionmethod developmentHomocysteine is found pri-
marily in plasma in the form of free homocysteine (HCy),
dimers, and analogue molecular forms bound by disulfide
bridges to proteins or other thiol-containing compounds. The
presence of these multiple forms complicates the development
of reliable analytical methods. One common approach con-
sists in the chemical reduction of all disulfide bonds to provide
a total homocysteine measurement. Total homocysteine is
therefore the sum of all homocysteine obtained from the re-
duction of these disulfide bonds; this also applies to total cys-
teine. Two reducing agents are frequently used for the reduc-
tion of disulfide bounds: DTT [22–26] and TCEP [27, 28].We
assessed both reducing agents and found that TCEP per-
formed best in terms of stability and extraction efficiency.
Indeed, TCEP provides a rapid chemical reduction of disulfide
bonds at room temperature without any pH adjustments [29].
Yet, a concentration of 200 mM TCEP was found not suffi-
cient to totally reduce the disulfide bonds, and the concentra-
tion was increased to 100 mg/mL [30]. Common solvents
such as MeOH and ACN [31] are reported for protein precip-
itation for the analysis of total homocysteine in blood with or
Table 1 Single reaction monitoring (SRM) transitions
Analyte RTa (min) SRM transitions
(m/z)
CE (eV)
Glycine 1.4 76→ 30 11
Glycine-d2 1.4 78→ 32 7
Serine 1.15 106→ 60 10
Serine-d3 1.15 109→ 63 11
Cysteine 1.4 122→ 59 20
Cysteine-d2 1.4 124→ 61 23
Taurine 0.6 126→ 108 11
Taurine-13C2 0.6 128→ 110 11
Homocysteine 2.85 136→ 90 10
Homocysteine-d4 2.85 140→ 94 10
Methionine 4.3 150→ 104 10
Methionine-d3 4.3 153→ 107 9
Pyridoxine 4.5 170→ 134 18
Pyridoxine-d2 4.5 172→ 136 19
Pyridoxamine 5.75 169→ 152 11
Pyridoxamine-d3 5.75 172→ 155 12
Homocysteic acid 0.6 184→ 138 10
Homocysteic acid-d4 0.6 188→ 142 9
Cystathionine 5.2 223→ 134 13
Cystathionine-d4 5.2 227→ 138 13
Riboflavin 3.4 377→ 243 15
Riboflavin-13C4
15N2 3.4 383→ 249 13
SAH 5.6 385→ 134 21
SAH-d4 5.6 389→ 136 18
SAM 5.9 399→ 250 14
SAM-d3 5.9 402→ 250 13
DMG 1.25 104→ 58 12
DMG-d6 1.25 110→ 64 15
Betaine 1.4 118→ 58 25
Betaine-d11 1.4 129→ 66 31
Choline 4.35 104→ 60 17
Choline-d9 4.35 113→ 69 19
5-MTHF 4.9 460→ 313 15
5-MTHF-13C5 4.9 465→ 313 26
a RT retention time given as information only
Table 2 Estimated limits of detection (LOD) and limits of quantitation
(LOQ) values from plasma and CSF samples spiked with labeled internal
standard (IS) solutions
Analyte In plasma In CSF
LOD LOQ Units LOD LOQ Units
Homocysteic acid 0.5 1.0 μM 0.25 0.5 μM
Taurine 2.0 3.0 μM 4.0 5.0 μM
Serine 2.0 3.0 μM 0.5 1.0 μM
Total cysteine 0.1 0.5 μM 0.05 0.125 μM
Glycine 2.0 3.0 μM 1.0 2.0 μM
Total homocysteine 1.0 2.0 μM 0.125 0.25 μM
Riboflavin 1.0 2.0 nM 4.0 5.0 nM
Methionine 2.0 3.0 μM 0.5 1.0 μM
Pyridoxine 2.0 3.0 nM 1.5 2.0 nM
Cystathionine 0.5 1.0 nM 0.5 1.0 nM
SAH 0.1 0.5 nM 2.0 4.0 nM
Pyridoxamine 2.0 3.0 nM 0.25 0.5 nM
SAM 2.0 3.0 nM 2.0 4.0 nM
DMG 2.0 4.0 μM 0.1 0.4 μM
Betaine 0.05 0.125 μM 0.01 0.02 μM
Choline 0.02 0.05 μM 0.05 0.1 μM
5-MTHF 6.0 8.0 nM 2.0 4.0 nM
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without the addition of acids such as FA. We found that
MeOH + 1 % FA gave on overall the best mass spectral peak
intensities and shapes.
Chromatography and mass spectra The chromatographic
method optimization is fully described in our previously
published paper [16]. In this method, retention of the most
polar compounds on a reversed-phase column was not
possible without the use of ion-pairing agents. Typical
chromatograms of a spiked CSF sample at the medium
level are shown in Fig. 2. Optimal selected reaction mon-
itoring (SRM) conditions were obtained in positive
electrospray ionization mode and are reported in Table 1.
Validation procedures. Estimated LOD and LOQ Due to
endogenous levels of some analytes and incomplete refer-
ence material for all the analyzed metabolites, the LOD
and LOQ were estimated by injecting plasma and CSF
Table 3 Repeatability and
intermediate trueness and
precision values at three different
concentration levels (n = 6 per
day, per level) to determine




Mean ± SD Units Recovery
± RSD (%)
CVr (%) CViR (%)
Homocysteic acid 15.0 15.0 ± 0.8 μM 100.2 ± 2.1 6.2 7.7
100.0 102.2 ± 3.9 102.2 ± 1.6 6.6 7.2
200.0 199.6 ± 7.3 99.8 ± 1.5 6.3 6.8
Taurine 30.0 29.6 ± 2.8 μM 98.6 ± 3.8 12.5 14.7
200.0 188.0 ± 14.3 94.0 ± 3.1 7.3 10.1
400.0 370.0 ± 24.0 92.5 ± 4.8 5.7 8.3
Serine 30.0 30.1 ± 0.8 μM 100.3 ± 1.1 7.9 7.7
200.0 203.4 ± 6.2 101.7 ± 1.2 3.2 4.3
400.0 405.6 ± 11.6 101.4 ± 1.2 4.1 4.7
Total cysteine 15.0 16.1 ± 0.9 μM 107.6 ± 4.1 14.1 14.0
100.0 101.5 ± 1.9 101.5 ± 0.8 7.9 7.5
200.0 191.4 ± 12.5 95.7 ± 2.7 7.1 9.2
Glycine 30.0 28.6 ± 1.8 μM 95.3 ± 2.6 15.2 15.2
200.0 197.9 ± 6.1 99.0 ± 1.3 5.1 5.6
400.0 399.9 ± 15.8 100.0 ± 1.6 4.8 5.9
Total homocysteine 15.0 14.6 ± 0.4 μM 97.5 ± 1.0 2.9 3.7
100.0 100.3 ± 1.7 100.3 ± 0.7 2.2 2.6
200.0 197.0 ± 5.0 98.5 ± 1.0 6.2 6.2
Riboflavin 30.0 29.5 ± 3.1 nM 98.3 ± 4.3 18.0 19.5
200.0 193.9 ± 10.2 97.0 ± 2.1 6.2 7.7
400.0 399.5 ± 28.0 99.9 ± 2.9 8.6 10.5
Methionine 15.0 15.2 ± 0.4 μM 101.4 ± 1.1 6.1 6.2
100.0 103.1 ± 2.4 103.1 ± 1.8 2.8 3.5
200.0 202.7 ± 5.9 101.4 ± 1.2 3.6 4.4
Pyridoxine 15.0 14.4 ± 0.4 nM 96.0 ± 2.4 9.1 8.8
100.0 100.8 ± 3.2 100.8 ± 1.3 4.0 4.8
200.0 194.8 ± 9.3 97.4 ± 1.9 5.2 6.7
Cystathionine 30.0 30.8 ± 1.9 nM 102.5 ± 2.5 17.2 16.8
200.0 194.7 ± 16.8 97.3 ± 3.5 9.7 12.4
400.0 388.3 ± 26.5 97.1 ± 2.8 8.6 10.4
SAH 30.0 30.8 ± 3.1 nM 102.6 ± 4.1 17.9 19.1
200.0 202.2 ± 11.2 101.1 ± 2.3 12.7 12.8
400.0 398.8 ± 25.0 99.7 ± 2.6 11.7 12.4
Pyridoxamine 15.0 13.5 ± 1.0 nM 90.3 ± 6.2 16.0 16.4
100.0 98.5 ± 4.4 98.5 ± 1.8 7.5 8.2
200.0 195.1 ± 11.3 97.5 ± 2.4 9.5 10.4
SAM 30.0 26.5 ± 2.0 nM 88.4 ± 7.2 18.5 18.5
200.0 200.6 ± 10.0 100.3 ± 2.0 12.1 12.1
400.0 415.9 ± 36.7 104.0 ± 3.6 10.1 12.7
DMG 5.0 4.9 ± 0.1 μM 97.6 ± 1.4 5.2 5.1
40.0 39.5 ± 2.0 98.7 ± 2.1 3.9 6.2
80.0 79.5 ± 2.2 99.3 ± 1.1 2.4 3.6
Betaine 12.5 12.6 ± 0.9 μM 100.7 ± 2.9 7.0 9.5
100.0 96.3 ± 2.3 96.3 ± 2.1 4.9 5.1
200.0 196.3 ± 5.0 98.1 ± 1.0 3.0 3.7
Choline 5.0 4.9 ± 0.2 μM 98.8 ± 1.3 5.3 5.8
40.0 39.4 ± 0.8 98.4 ± 0.8 4.2 4.3
80.0 79.4 ± 1.7 99.2 ± 0.9 1.4 2.5
5-MTHF 50.0 47.8 ± 2.7 nM 95.7 ± 2.3 15.1 14.9
400.0 393.0 ± 26.5 98.3 ± 2.7 12.8 13.5
800.0 804.4 ± 26.8 100.5 ± 1.4 10.5 10.2
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samples spiked by serial dilution of IS solution until
reaching a S/N above 3 for the LOD and above 10 for
the LOQ. Stable isotope-labeled compounds have the same
physico-chemical properties and should therefore have the
same analytical behavior as the analogue molecules (e.g.,
retention time, intensity). Estimated LOD and LOQ values
from plasma and CSF samples spiked with IS solutions
are reported in Table 2.
Linearity of the calibration We assessed whether to use
solvent-based calibration curves or matrix-matched external
calibration curves to accurately quantitate our 17 metabolites.
Calibration curves were therefore performed in both solvent
and sample matrix (plasma and CSF) using 7 calibration
levels. The plasma or CSF calibration slopes differed by less
than 16 % from the solvent-based calibration curves. Without
IS correction, these differences would have been far higher in
Table 4 Repeatability and
intermediate trueness and
precision values at three different
concentration levels (n = 6 per
day, per level) to determine




Mean ± SD Units Recovery
± RSD (%)
CVr (%) CViR (%)
Homocysteic acid 12.5 12.9 ± 0.3 μM 103.2 ± 1.8 6.7 6.5
100.0 102.4 ± 4.2 102.4 ± 1.7 4.8 6.0
200.0 200.7 ± 8.5 100.4 ± 1.7 3.9 5.5
Taurine 25.0 25.4 ± 0.5 μM 101.7 ± 0.9 8.8 8.3
200.0 199.4 ± 10.6 99.7 ± 2.2 5.0 7.0
400.0 386.5 ± 16.7 96.6 ± 1.8 3.1 5.2
Serine 25.0 24.5 ± 1.1 μM 98.1 ± 1.7 6.5 7.3
200.0 202.6 ± 5.9 101.3 ± 1.2 3.8 4.6
400.0 402.8 ± 14.3 100.7 ± 1.4 2.7 4.3
Total cysteine 12.5 12.7 ± 0.4 μM 101.3 ± 1.4 4.7 5.4
100.0 102.8 ± 3.0 102.7 ± 1.2 3.2 4.2
200.0 201.0 ± 4.9 100.5 ± 1.0 2.7 3.5
Glycine 25.0 25.2 ± 1.3 μM 100.7 ± 2.1 5.3 7.0
200.0 201.7 ± 6.0 100.8 ± 1.2 3.4 4.3
400.0 393.3 ± 8.3 98.3 ± 0.9 2.5 3.1
Total homocysteine 12.5 12.4 ± 0.6 μM 99.2 ± 1.9 2.6 5.3
100.0 102.7 ± 1.8 102.7 ± 1.5 3.5 3.7
200.0 202.4 ± 4.4 101.2 ± 0.9 2.2 2.9
Riboflavin 25.0 25.4 ± 2.8 nM 101.7 ± 4.5 16 18.3
200.0 202.1 ± 7.8 101.0 ± 1.6 11.7 11.4
400.0 402.5 ± 23.8 100.6 ± 2.4 7.8 9.2
Methionine 12.5 12.9 ± 0.6 μM 103.0 ± 1.8 4.9 6.3
100.0 104.2 ± 4.2 104.2 ± 1.6 3.4 5.1
200.0 203.9 ± 6.5 102.0 ± 1.3 3.4 4.5
Pyridoxine 12.5 12.6 ± 0.3 nM 100.9 ± 0.9 6.6 6.4
100.0 102.3 ± 4.3 102.3 ± 1.7 3.9 5.5
200.0 200.7 ± 6.8 100.4 ± 1.4 3.3 4.5
Cystathionine 25.0 24.1 ± 1.0 nM 96.5 ± 1.6 11.4 11.1
200.0 213.9 ± 16.3 107.0 ± 3.1 7.2 10.1
400.0 433.1 ± 28.4 108.3 ± 4.7 7.1 9.2
SAH 50.0 48.1 ± 3.5 nM 96.3 ± 3.0 12.8 13.8
400.0 403.8 ± 14.3 100.9 ± 1.4 6.9 7.2
800.0 773.0 ± 18.5 96.6 ± 2.0 6.9 6.7
Pyridoxamine 12.5 12.1 ± 0.4 nM 96.8 ± 2.0 9.9 9.5
100.0 101.3 ± 3.5 101.3 ± 1.4 7.8 7.9
200.0 200.0 ± 8.8 100.0 ± 1.8 7.6 8.2
SAM 50.0 51.1 ± 4.4 nM 102.1 ± 3.5 13.9 15.3
400.0 406.2 ± 19.1 101.6 ± 1.9 8.5 9.1
800.0 807.2 ± 41.6 100.9 ± 2.1 5.9 7.5
DMG 5.0 5.0 ± 0.2 μM 99.8 ± 1.2 3.1 4.1
40.0 40.6 ± 1.1 101.5 ± 1.1 3.2 4.0
80.0 80.8 ± 2.1 101.0 ± 1.0 2.8 3.6
Betaine 5.0 5.2 ± 0.2 μM 102.5 ± 1.5 5.2 6.1
40.0 41.1 ± 1.0 102.8 ± 1.7 3.2 3.8
80.0 80.5 ± 2.6 100.7 ± 1.3 2.3 3.8
Choline 5.0 5.0 ± 0.1 μM 100.2 ± 1.2 4.9 5.3
40.0 40.7 ± 1.0 101.8 ± 1.0 3.1 3.8
80.0 79.9 ± 1.0 99.9 ± 0.5 2.9 3.0
5-MTHF 50.0 49.5 ± 3.9 nM 99.1 ± 3.2 12.5 13.9
400.0 408.0 ± 7.7 102.0 ± 0.8 5.7 5.5
800.0 818.2 ± 29.8 102.3 ± 1.5 3.8 5.0
High-throughput and simultaneous quantitative analysis 301
such complex matrices. These results show the importance of
using isotopically labeled compounds as spiked IS to efficient-
ly compensate for the matrix effect. For simplicity, only water-
based calibration curves were used during this validation to
accurately quantify these analytes in plasma or CSF samples.
The linearity of the calibration curves was assessed using
seven calibration levels with five replicates each. The relation-
ship between analyte response and concentration was linear in
the solvent in the range mentioned in Table S2 (see ESM). For
all compounds including the additional compounds, i.e.,
DMG, betaine, choline, and 5-MTHF, a linear regression
model was used. A weighting factor of 1/x was applied for
all compounds to achieve a linear model with the lowest rel-
ative errors at each level. All coefficients of determination (r2)
were found above 0.99. The acceptance criterion for each
back-calculated standard concentration was ±15 % deviation
from the nominal value except at the lowest level, i.e., level 1,
which was set at ±20 %. All values were found within these
ranges with a maximum of 2 excluded calibration points per
curve.
Trueness, precision, and recovery Values for trueness and
precision are summarized in Tables 3 and 4. For plasma sam-
ples, within-run precision (repeatability r) and between-run
precision (intermediate reproducibility iR) CV values were
found below 20 % for the lowest spiking level and below
15 % for the medium and high spiking levels, which are with-
in the recommended limits [32]. For CSF samples, r and iR
values were found below 16% for the lowest spiking level and
below 12 % for the medium and high spiking levels.
Recoveries were found between 90 and 108 % for plasma
samples and between 96 and 109 % for CSF samples, which
are also within the recommended limits.
Matrix effectsMatrix effectsmay occur in anyLC–MSanalysis
because of the presence of co-eluting compounds in the sample
Table 5 Plasma and CSF
concentrations of 17 metabolites
in control and AD subjects (mean
± SD)
Analyte Plasma CSF Units
Control (n = 6) AD (n = 6) Control (n = 6) AD (n = 6)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Homocysteic acid <LOD <LOD <LOD <LOD μM
Taurine 81.5 ± 30.9 71.6 ± 18 27.8 ± 4.7 24.0 ± 4.8 μM
Serine 79.6 ± 15.7 85.8 ± 19.4 25.4 ± 4.8 32.9 ± 14.5 μM
Total cysteine 144.4 ± 9.9 153.2 ± 32.9 1.1 ± 0.4 2.4 ± 2.2 μM
Glycine 250.0 ± 112.1 339.3 ± 180.6 7.8 ± 4.4 25.6 ± 20.3 μM
Total homocysteine 5.3 ± 1.6 8.1 ± 6.9 <LOQ <LOQ μM
Riboflavin 68.2 ± 66.6 21.9 ± 30.7 6.7 ± 5.3 12.9 ± 6.5 nM
Methionine 16.9 ± 2.8 16.8 ± 3.4 3.7 ± 0.4 5.3 ± 1.6 μM
Pyridoxine <LOD <LOD <LOD <LOD nM
Cystathionine 116.7 ± 34.2 175.7 ± 112.3 46.0 ± 36.7 42.0 ± 32.9 nM
SAH 25.7 ± 9.9 40.9 ± 9.8 14.3 ± 2.5 26.1 ± 9.4 nM
Pyridoxamine <LOD <LOD <LOD <LOD nM
SAM 88.5 ± 18.1 68.5 ± 19.4 191.4 ± 31.1 150.7 ± 30.2 nM
DMG <LOQ <LOQ <LOQ <LOQ μM
Betaine 45.9 ± 14.5 45.8 ± 17.0 <LOD <LOD μM
Choline 11.2 ± 3.5 11.6 ± 3.7 3.0 ± 0.7 3.5 ± 0.5 μM
5-MTHF 56.6 ± 23.3 191.9 ± 363.5 60.9 ± 11.8 57.4 ± 18.8 nM
Fig. 3 Plots in plasma samples.
Concentrations for glycine and
total homocysteine are in
micromolars and for SAH and
SAM in nanomolars. P values are
reported
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matrix, especially in complex matrices such as plasma. The use
of stable isotope-labeled related compounds as IS is a well-
known efficient approach to overcome and correct matrix effects
and therefore improve the method’s accuracy [33]. Although
stable isotope-labeled compounds were used in our method, we
still evaluated ion suppression and enhancement. Besides, ion
suppression may still occur when using ion pairing such as
heptafluorobutyric acid. Quantitative measurements for estimat-
ing the matrix effects are presented in Table S6 in the ESM.
Application to biological samples
The homocysteine–methionine cycle is of particular importance
for cognitive function and Alzheimer’s disease. For instance, an
imbalance of this metabolic pathway, marked by hyperhomocys-
teinemia and/or an altered SAM/SAH ratio, is a hallmark of
memory loss and cognitive decline in elderly populations [34,
35] This loss of metabolic homeostasis may result from deficien-
cy in metabolites and co-factors—such as vitamin B12 or folic
acid—directly and indirectly involved in the methylation of ho-
mocysteine. An increased interest exists to decipher their role as
potential biomarkers of neurodegeneration in Alzheimer’s dis-
ease [36–38]. The robustness of our method for the sensitive
detection and quantitation of the 17 metabolites and co-factors
of methionine metabolism was assessed in biological materials
collected from healthy donors and patients diagnosed with
Alzheimer’s disease. We reported in Table 5 plasma and CSF
concentrations for the 17metabolites in control and AD subjects.
In blood plasma andCSF, the ADpatients showed a significantly
higher concentration of SAH compared to healthy subjects, but a
lower circulating concentration of SAM (Figs. 3 and 4), a feature
that was reported previously by other authors in several larger
clinical studies using different and complementary assays
[39–41]. However, despite the lack of statistical significance,
our analysis also showed a trend toward a higher plasma level
of homocysteine in those affected patients. In addition, a signif-
icant increase in glycine concentration in CSF was observed in
AD patients, an observation that was confirmed by a similar
trend in plasma samples. This metabolic pattern has also been
reported previously by other authors using a targeted analytical
method for amino acids [42]. Therefore, this application to real
biological samples, although limited due to the number of sub-
jects, demonstrated the importance of capturing sensitive meta-
bolic readouts and contributed to obtain complete individual
clinical phenotypes in plasma and CSF. Knowledge of the me-
tabolites and co-factor distribution between plasma andCSFmay
yield information to better understand the impact of metabolic
dysregulation and vitamin deficiencies/insufficiencies in the con-
text of aging, cardiometabolic, and cognitive health research.
Conclusions
Aprecise evaluation of changes in the homocysteine–methionine
pathway is key to understand the relation among diet, nutrition
andmetabolic requirements, and cardiometabolic or neurological
disorders. Quantitation of elements of this pathway is often cov-
ered by several analytical methods that just cover it partially. To
fill this analytical gap, we have developed a robust, high-
throughput LC–MS/MS method for the quantitation of 17 key
metabolites embedded into the homocysteine–methioninemetab-
olism. The approach described here provides a novel analytical
tool allowing scientists to capture in one single analysis changes
in the homocysteine–methionine pathway and their co-factors in
plasma and CSF samples. The proposed analytical method does
this with a high level of accuracy and reproducibility, making it
especially interesting for large epidemiologic studies.
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